This report provides an overview of the pharma market in Brazil including key industry and regulatory trends, deals, clinical trials, marketed drugs, pipeline drugs, contract manufacturing, market access, and key players
Brazil has the largest pharma market in Central/Southern America and is the 12th largest pharmaceutical market in the world, with the 2022 election results likely to boost the pharma market.
Brazil is an untapped market for big pharma manufacturing, with domestic companies dominating the marketed products landscape as encouraged by government policy.
The top therapy areas among marketed and pipeline products in Brazil are central nervous system (CNS) and infectious disease, respectively.
Brazil has the largest pharma market in Central/Southern America and is the 12th largest pharmaceutical market in the world, with the 2022 election results likely to boost the pharma market.
Brazil is an untapped market for big pharma manufacturing, with domestic companies dominating the marketed products landscape as encouraged by government policy.
The top therapy areas among marketed and pipeline products in Brazil are central nervous system (CNS) and infectious disease, respectively.
Key Highlights
- Brazil has the largest pharma market in Central/Southern America and is the 12th largest pharmaceutical market in the world, with the 2022 election results likely to boost the pharma market.
- Brazil is an untapped market for big pharma manufacturing, with domestic companies dominating the marketed products landscape as encouraged by government policy.
- The top therapy areas among marketed and pipeline products in Brazil are central nervous system (CNS) and infectious disease, respectively.
Scope
- This report provides an assessment of the major industry, and regulatory trends shaping the Brazil pharma industry.
- It provides a detailed analysis of deals, clinical trials, marketed and pipeline products, and contract manufacturing.
- It also provides an overview of key regulatory and market access information, market drivers and barriers, and key players in the Brazilian pharma sector.
Reasons to Buy
- Identify the trends that are shaping the Brazil pharma market and driving innovation, including key government policies and strategic initiatives.
- Identify key current and emerging players in the Brazil pharma market
- Develop in-licensing and out-licensing strategies, using a detailed overview of current deals
- Understand the challenges and strategies impacting the development of therapy agents, and market access in Brazil
- Get an analysis of Brazil's manufacturing and outsourcing sector
Table of Contents
1 Table of Contents1.1 Preface
1.1.1 Table of Contents
1.1.2 Abbreviations
1.1.3 Related Reports
1.2 Executive Summary
1.2.1 Key findings
1.3 Introduction
1.3.1 Brazil’s pharma market: Growing capabilities but still untapped by large international companies
1.3.2 Key influencer Twitter chat related to Brazil
1.4 Trends
1.4.1 Industry trends - Brazil is an untapped market for big pharma manufacturing
1.4.2 Industry trends - 2022 election results should help boost the pharma industry
1.4.3 Industry trends - The Brazil pharma market is dominated by generics
1.4.4 Industry trends - CNS and infectious disease lead the pharma market
1.4.5 Industry trends - Growing levels of R&D innovation
1.4.6 Industry trends - Increasing investment in healthtech
1.4.7 Industry trends - Domestic pharma companies dominate in Brazil
1.4.8 Regulatory trends - Regulatory trends in Brazil
1.4.9 Regulatory trends - Overcoming counterfeiting of medicines
1.5 Value Chain
1.6 Market Analysis
1.6.1 Brazil’s pharma market will see moderate growth up to 2030
1.6.2 Strategic alliances are the leading deal type in Brazil
1.6.3 Licensing agreements lead strategic alliance activity in Brazil
1.6.4 Top 10 licensing agreements involving Brazil by value, 2018-22 YTD
1.6.5 Asset transactions lead with majority of M&A deals in Brazil
1.6.6 Minimal capital raising and CSA activity in Brazil
1.7 Clinical Trials
1.7.1 The number of clinical trials in Brazil
1.7.2 The majority of trials in Brazil are mid/late phase
1.7.3 Infectious disease indications dominate clinical trials in Brazil
1.7.4 Major sponsors of clinical trials in Brazil
1.7.5 Top 10 clinical trial sites in Brazil by historical volume
1.7.6 Top 10 clinical trial investigators in Brazil by historical volume
1.7.7 Top 10 trials in Brazil by completed enrollment since 2019
1.8 Marketed Products
1.8.1 The US is the largest importer of pharmaceuticals from Brazil
1.8.2 Generics have the largest share of marketed drugs in Brazil
1.8.3 CNS disorders lead marketed drugs in Brazil
1.8.4 Leading drug developers in Brazil
1.8.5 The majority of marketed biologics in Brazil target infectious disease
1.8.6 Examples of Brazil approved biologics
1.8.7 Brazil in top 10 countries of COVID-19 vaccinations administered
1.8.8 Currently approved COVID-19 vaccines in Brazil
1.9 Pipeline Products
1.9.1 Majority of pipeline drugs are in Phase III and most are innovator biologics
1.9.2 Butantan Institute leads in pipeline products in Brazil
1.9.3 Infectious disease leads pipeline drug development in Brazil
1.9.4 Most pipeline biologics are in the infectious disease space
1.9.5 Pipeline COVID-19 vaccines and treatments in Brazil
1.9.6 Examples of pipeline COVID-19 vaccines and other treatments in Brazil
1.10 Contract Manufacturing in Brazil
1.10.1 Contract manufacturing companies and facilities in Brazil
1.10.2 CDMO facilities distribution in Brazil
1.11 Regulatory and Market Access
1.11.1 Overview of healthcare system in Brazil
1.11.2 Organization of healthcare system in Brazil
1.11.3 Drug approval process in Brazil
1.11.4 Regulation of drugs in Brazil - Generics
1.11.5 Regulation of drugs in Brazil - Biologics and biosimilars
1.11.6 Market access for drugs in Brazil - Drug pricing
1.11.7 Market access for drugs in Brazil - Reimbursement
1.11.8 Market access for drugs in Brazil - Regulatory landscape
1.12 Market Drivers and Barriers
1.12.1 Market drivers in Brazil
1.12.2 Market barriers in Brazil
1.13 Companies
1.13.1 Eurofarma
1.13.2 EMS
1.13.3 Medley
1.13.4 Aché
1.13.5 Novartis
1.13.6 Pfizer
1.13.7 Hypera
1.13.8 Cristalia
1.14 Appendix
1.14.1 Bibliography
1.14.2 Key themes impacting the pharmaceutical industry
1.14.3 Our thematic research methodology
1.14.4 About the authors
1.14.5 About the Publisher
1.14.6 Trusted intelligence in uncertain times
1.14.7. Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Catalent Inc
- Patheon NV
- Merieux NutriSciences Corp
- EMS
- Hypera
- Medley Industria Farmaceutica
- Europharma Laboratorios
- Aché Laboratorios Farmaceuticos
- Synova Pesquisa Cientifica
- Blau Farmaceutica
- Diagnosticos da America
- AstraZeneca
- Eisai
- F. Hoffmann-La Roche
- Novartis
- Germed Pharma
- Legrand Pharma
- Sanofi
- Pfizer
- Butantan Institute
- JCR Pharmaceuticals
- Uniao Quimica Farmaceutica Nacional
- Cristalia Produtos Quimicos Farmaceuticos
